What is the recommended treatment regimen for latent tuberculosis infection in India?

Treatment Recommendation for Latent TB in India

For latent tuberculosis infection (LTBI) treatment in India, the preferred regimen is 3 months of once-weekly isoniazid plus rifapentine (3HP), which offers excellent efficacy with higher completion rates due to its shorter duration, though weight-based dosing and pyridoxine co-administration should be strongly considered given safety concerns in lower-weight Indian populations. 1

Preferred Treatment Regimens (in order of priority)

First-Line: 3HP (3 months isoniazid + rifapentine, once weekly)

• Strong recommendation with moderate evidence 1
• Offers the best balance of efficacy, tolerability, and completion rates
• Critical caveat for India: Higher rates of systemic drug reactions (SDRs) including dizziness, flu-like symptoms, hypotension, and syncope have been reported in Asian populations, particularly those with low BMI 2
• In Delhi, 19% (118/614) of household contacts reported dizziness on 3HP 2
• Practical modifications needed: Consider weight-based dosing instead of fixed 900mg isoniazid dose in adults, and add pyridoxine supplementation to reduce SDRs 2

Second-Line: 4 months daily rifampin

• Strong recommendation with moderate evidence for HIV-negative individuals 1
• Excellent alternative when 3HP is not tolerated or contraindicated
• Fewer drug interactions than rifapentine in some contexts

Third-Line: 3 months daily isoniazid + rifampin

• Conditional recommendation (very low evidence for HIV-negative, low evidence for HIV-positive) 1
• Particularly effective in children <15 years, showing similar efficacy to 6-month isoniazid with no difference in hepatotoxicity 1
• Warning: Hepatotoxicity risk may be higher with combination than either drug alone 1

Alternative Regimens

6 months daily isoniazid

• Strong recommendation for HIV-negative; conditional for HIV-positive 1
• Proven efficacy but lower completion rates due to longer duration
• More hepatotoxicity in adults than children 1

9 months daily isoniazid

• Conditional recommendation for all populations 1
• May be slightly more effective than 6 months but no direct comparative data
• Lowest completion rates due to longest duration

Special Considerations for India

High-risk groups requiring LTBI screening and treatment:

• Household contacts of drug-susceptible TB cases (all ages ≥5 years now included in national program) 3, 4
• Children <5 years (long-standing priority)
• People living with HIV
• Immunosuppressed individuals 5, 4

Programmatic implementation insights:

• LTBI prevalence in household contacts: approximately 61.5% by TST 3
• Acceptance rates for TPT initiation: 95.6% when offered 3
• Treatment completion rates with 3HP: 91.8% in real-world Delhi settings 3
• Major barrier: lack of risk perception among asymptomatic contacts 3

Critical Safety Monitoring for 3HP in India

Given the concerning safety signals in Asian populations 2:

Before initiating 3HP:

• Document body weight and calculate weight-based dosing if BMI <18.5
• Check acetylator status if feasible (slow acetylators at higher risk)
• Always co-administer pyridoxine (not standard in current WHO guidelines but recommended for Indian context)

During treatment:

• Educate patients about SDRs: dizziness, flu-like symptoms, hypotension
• Establish pharmacovigilance reporting systems 2
• Lower threshold for switching to alternative regimen if SDRs occur

Algorithm for Regimen Selection

1. First choice: 3HP with weight-based dosing + pyridoxine

   • If SDRs develop → switch to 4 months rifampin

2. If rifapentine unavailable or contraindicated: 4 months daily rifampin

3. If rifampin contraindicated (drug interactions): 6-9 months isoniazid

4. For children <15 years: Consider 3 months daily isoniazid + rifampin as equally effective alternative to longer isoniazid 1

5. For HIV-positive patients: 3HP remains preferred, but monitor drug-drug interactions with antiretrovirals carefully 1

Common Pitfalls to Avoid

• Fixed dosing trap: Don't use fixed 900mg isoniazid in low-weight adults without considering weight-based adjustment 2
• Pyridoxine omission: Unlike Western populations, Indian patients may benefit more from routine pyridoxine supplementation with 3HP 2
• Inadequate TB disease exclusion: Always rule out active TB before initiating TPT to prevent acquired drug resistance 1
• Lost to follow-up at screening: Maximum attrition occurs at TST screening stage; home-based testing improves participation 3, 6

The Indian National TB Elimination Program adopted these WHO recommendations in 2021 and has expanded TPT to include adolescents and adult household contacts beyond the traditional focus on children <5 years and PLHIV 5, 4.